Oncology · Dermatology · 59 min ago
Five-year RELATIVITY-047 results support durable benefit with nivolumab–relatlimab
A prespecified five-year analysis of the phase 3 RELATIVITY-047 trial compared nivolumab plus relatlimab with nivolumab alone in 714 patients with advanced melanoma. The combination continued to show advantages in progression-free, overall and melanoma-specific survival; exploratory biomarker findings suggested differences by LAG-3 and CD8 cell levels.
- Five-year follow-up showed continued survival advantages with combination therapy.
- PFS, OS and melanoma-specific survival favored nivolumab plus relatlimab.
- Biomarker analyses were exploratory and do not establish treatment selection.
RELATIVITY-047 was a randomized, double-blind phase 2–3 trial in patients with metastatic or unresectable melanoma. Participants received nivolumab plus relatlimab (355 patients) or nivolumab alone (359 patients) every four weeks. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), response and safety. This prespecified analysis had a minimum follow-up of 57.3 months.
Compared with nivolumab alone, the combination was associated with improved PFS (hazard ratio [HR] 0.77, 95% CI 0.65–0.92), OS (HR 0.78, 95% CI 0.64–0.95) and melanoma-specific survival (HR 0.71, 95% CI 0.57–0.88). The authors reported that the safety profile remained consistent with earlier reports.
Exploratory biomarker analyses found that, among biomarker-evaluable patients with PD-L1 expression of at least 1%, high peripheral or tumor LAG-3-positive CD8 cell levels were associated with worse outcomes on nivolumab alone. The combination was also associated with a lower prevalence of primary resistance. These biomarker findings are exploratory and do not establish a treatment-selection test; the reported survival results provide longer-term evidence for the combination in advanced melanoma. The trial is registered as NCT03470922.
In practice
For patients with metastatic or unresectable melanoma, this prespecified five-year analysis of a randomized trial found that nivolumab plus relatlimab continued to have better PFS, OS and melanoma-specific survival than nivolumab alone. These long-term results reinforce evidence for the combination in this population, but the source provides hazard ratios rather than absolute survival rates. The LAG-3/CD8 findings are exploratory and do not establish a biomarker-based method for choosing treatment.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Nature Medicine: Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.